Outside of HIV, Gilead's oncology franchise ended the year in the growth category, as well. The company's cancer treatments pulled down $843 million in fourth-quarter sales, representing a 10% ...

Feb 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday ...

Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences GILD, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Gilead Sciences handily beat the consensus Wall Street earnings estimate for Q4. The company projects much higher earnings in full-year 2025. Income and value investors could like this biotech ...

As reported by Deadline on February 10, 2025, American actor Jesse Garcia and Korean American actor and martial artist Yun Lee, are set to join the cast of The Odyssey. Their roles in the movie ...

Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our prepared ...

EXCLUSIVE: Jesse Garcia (The Mother, Flamin’ Hot) and Will Yun Lee (San Andreas, The Good Doctor) have joined the cast of Christopher Nolan‘s The Odyssey from Universal, sources close to ...

Gilead Sciences (NASDAQ:GILD), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus estimates.

Gilead Sciences (GILD) reported $7.57 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 6.4%. EPS of $1.90 for the same period compares to $1.72 a ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments. A key highlight was the robust performance in the HIV and oncology segments ...

Drug maker Gilead (GILD) is rallying 7.5% after the company reported stronger-than-expected fourth-quarter results and provided 2025 earnings per share guidance that came in above analysts ...